CSIMarket
 


Quidelortho Corp  (QDEL)
Other Ticker:  
 

Quidelortho's Quick Ratio

QDEL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 0.22 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Quidelortho in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 2196 to 3085.

Explain Quick Ratio?
How much Cash & cash equivalents QDELīs has?
What are QDELīs Current Liabilities?


QDEL Quick Ratio (Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
(Oct 02 2022)
III. Quarter
Y / Y Current Liabilities Change -1.46 % -12.22 % 84.27 % 211.26 % 193.75 %
Y / Y Cash & cash equivalent Change -26.82 % -48.16 % -69.94 % -58.36 % -54.36 %
Quick Ratio MRQ 0.22 0.28 0.44 0.34 0.3
QDEL's Total Ranking # 3085 # 2196 # 2447 # 2154 # 4035
Seq. Current Liabilities Change 8.86 % -12.98 % -9.85 % 15.39 % -3.03 %
Seq. Cash & cash equivalent Change -13.63 % -43.61 % 14.99 % 30.68 % -38.82 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 17
Healthcare Sector # 894
Overall Market # 3085


Quick Ratio Statistics
High Average Low
6.86 2.21 0.22
(Jun 30 2016)   (Oct 01 2023)




Financial Statements
Quidelortho's Current Liabilities $ 860 Millions Visit QDEL's Balance sheet
Quidelortho's Cash & cash equivalent $ 193 Millions Visit QDEL's Balance sheet
Source of QDEL's Sales Visit QDEL's Sales by Geography


Cumulative Quidelortho's Quick Ratio

QDEL's Quick Ratio for the trailling 12 Months

QDEL Quick Ratio

(Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
(Oct 02 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -1.46 % -12.22 % 84.27 % 211.26 % 193.75 %
Y / Y Cash & cash equivalent TTM Growth -26.82 % -48.16 % -69.94 % -58.36 % -54.36 %
Quick Ratio TTM 0.33 0.34 0.39 0.72 1.1
Total Ranking TTM # 3869 # 5593 # 3696 # 2507 # 5409
Seq. Current Liabilities TTM Growth 8.86 % -12.98 % -9.85 % 15.39 % -3.03 %
Seq. Cash & cash equivalent TTM Growth -13.63 % -43.61 % 14.99 % 30.68 % -38.82 %


On the trailing twelve months basis In spite of the year on year decrease in QDEL's Current Liabilities to $860.00 millions, cumulative Quick Ratio to 0.33 below the QDEL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Quidelortho. While Quick Ratio overall ranking has improved so far to 3869, from total ranking during the twelve months ending second quarter 2023 at 5593.

Explain Quick Ratio?
How much Cash & cash equivalents QDELīs has?
What are QDELīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 17
Healthcare Sector # 1033
Within the Market # 3869


trailing twelve months Quick Ratio Statistics
High Average Low
6.08 2.29 0.28
(Sep 30 2016)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Oct 01 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioOct 01 2023 MRQ Cash & cash equivalentOct 01 2023 MRQ Current Liabilities
Volitionrx Limited  0.61 $ 10.809  Millions$ 17.654  Millions
Immucell Corp  0.60 $ 1.989  Millions$ 3.328  Millions
Navidea Biopharmaceuticals Inc   0.48 $ 3.865  Millions$ 7.979  Millions
Myriad Genetics Inc   0.41 $ 86.300  Millions$ 209.300  Millions
Idexx Laboratories Inc  0.34 $ 331.696  Millions$ 970.193  Millions
Quidelortho Corp  0.22 $ 193.200  Millions$ 860.000  Millions
Burzynski Research Institute Inc  0.22 $ 0.001  Millions$ 0.006  Millions

Date modified: 2023-11-03T20:15:38+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com